N
Novadip Biosciences
Regenerative stem cell therapies for critical bone defects
About Novadip Biosciences
Novadip Biosciences is a Belgian late-stage clinical regenerative medicine company spun out of UCLouvain and St. Luc University Hospital in 2013 by Dr Denis Dufrane. Its 3M³ platform uses adipose-derived stem cells in a scaffold-free extracellular matrix to treat large bone defects; lead candidates include autologous NVD-003 for congenital pseudarthrosis of the tibia (pivotal Phase 3) and allogeneic NVD-X3 for trauma and spinal fusion. In September 2026 Novadip closed a €10.4 million (~$12 million) convertible financing led by New Science Ventures with Fund+, Wallonie Entreprendre, VIVES, ORSA Tech, Sambrinvest, Noshaq and Invest.BW, following a €9.6 million convertible loan the prior year (~€20 million convertible since June 2025). Hitting the target unlocks a tranche of an €18 million EIB venture-debt facility; the company cites about €137 million cumulative equity and non-dilutive funding. Sources: EU-Startups 21 Sep 2026; company.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2013
- Headquarters
- Mont-Saint-Guibert, Belgium
- Employees
- 58
- Open positions
- 3
- Dealroom signal
- 80.2/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices
- Sector
- Biotech & Life Sciences, Biotechnology, Stem Cells, Regenerative Medicine, Spinout, DT and LS, science-based
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| DEBTDebt | Dec 2023 | $20M | — | European Investment Bank | ↗ |
| GRANTOther financing | Nov 2022 | $18M | — | Public Service of Wallonia | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Novadip Biosciences is 7.6K monthly website visits, up 1753.7% over the last three months. Novadip Biosciences's team grew 0% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Public Service of Wallonia
Series A11 investors entered at this stage
New Science Ventures
Integrale Advisors
Invest.BW
FundPlus- CFCR-CP Life Science Fund
Vives Partners
Investsud- OROlivier van der Rest
Wallonie Entreprendre
WE Venture
Pierre Drion
Series B and later1 investor entered at this stage
European Investment Bank
Other known investors2 additional known investors
Cliniques Universitaires Saint-Luc Asbl
UCLouvain
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Novadip Biosciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Novadip Biosciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.